Y-Mabs Therapeutics Inc

NASDAQ:YMAB   3:59:59 PM EDT
47.40
-2.58 (-5.16%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.92B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$11.59 Million
Adjusted EPS-$0.46
See more estimates
10-Day MA$49.92
50-Day MA$49.67
200-Day MA$41.83
See more pivots

Y-mAbs Therapeutics, Inc. Stock, NASDAQ:YMAB

750 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY 10017
United States of America
Phone: 212-847-9841
Number of Employees: 32
www.ymabs.com

Description

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.